BioMoti is featured in sp2 Inter-Active May/June 2013 issue

Dr Davidson Ateh, CEO, discusses BioMoti’s Oncojan™ intracellular drug delivery technology for cancer treatment with Tom Mulligan, Editor, in the May/June 2013 edition of sp2 Inter-Active. The article explores the origins of BioMoti, it’s technological capabilities, lead ovarian cancer candidate, business model, growth plans and the current context for early stage UK biotech companies. Click for article: BioMoti […]

Read more